Sound Medical Weight Loss is pleased to offer oral Wegovy®, a newly FDA-approved tablet form of semaglutide, expanding access to one of the most effective anti-obesity therapies available. Approved in late December, oral Wegovy is now available at pharmacies nationwide—and we are implementing it immediately for appropriate patients who prefer a non-injectable option.
Oral Wegovy delivers the same GLP-1 receptor agonist used in the injectable formulation, but in a once-daily pill. This makes it an appealing choice for patients who:
As reported in JAMA:
“Participants with obesity or overweight who received the drug lost an average of about 14% of their body weight, compared with about 2% in the placebo group.”
— Schweitzer K., JAMA, January 16, 2026
These results reinforce what we already know: GLP-1 therapies don’t just support weight loss—they help correct the underlying metabolic and hormonal drivers of obesity.
Oral Wegovy pricing currently ranges from $149 per month to $299 per month for the highest doses, based on published manufacturer pricing through Novo Nordisk. This positions oral Wegovy as a more accessible option for many patients, particularly those paying out of pocket or looking for flexibility within their treatment plan.
At Sound Medical Weight Loss, we don’t believe in one-size-fits-all care. Our team carefully evaluates whether oral Wegovy is the right tool based on your medical history, metabolic health, goals, and lifestyle. For some patients, it may be a starting point. For others, a maintenance or bridge option. Always, it’s part of a medically guided, personalized plan.
If you’re curious whether oral Wegovy could be right for you, our team is ready to guide you—clearly, thoughtfully, and without stigma—every step of the way.
We are excited to help our patients every step of the way on their journey to weight loss, and that starts with your First Visit. We will get to know you and your health and lifestyle goals so we can make a detailed treatment plan. Patients with a medical history that includes pancreatitis or certain types of cancer are likely not eligible for this treatment, so it’s important to share your full medical history with your provider.
